RORγt controls the differentiation of T H 17 cells, which are mediators of autoimmune conditions such as experimental autoimmune encephalomyelitis (EAE). RORγt also regulates thymocyte development and lymph node genesis. Here we show that the function of RORγt is regulated by its sumoylation. Loss of Sumo3, but not Sumo1, dampens T H 17 differentiation and delays the progression of thymic CD8 + immature single-positive cells (ISPs). RORγt is SUMO3-modified by E3 ligase PIAS4 at lysine 31 (K31), and the mutation of K31 to arginine in mice prevents RORγt sumoylation, leading to impaired T H 17 differentiation, resistance to T H 17-mediated EAE, accumulation of thymic ISPs, and a lack of Peyer's patches. Mechanistically, sumoylation of RORγt-K31 recruits histone acetyltransferase KAT2A, which stabilizes the binding of SRC1 to enhance RORγt transcription factor activity. This study thus demonstrates that sumoylation is a critical mechanism for regulating RORγt function, and reveals new drug targets for preventing T H 17-mediated autoimmunity.
T he transcription factor RORγt directs the differentiation of T H 17 cells, which secrete IL-17 and participate in both protective and pathological immunity 1 . The clearance of pathogens such as Citrobacter rodentium and fungus depends on robust protective T H 17 immunity [2] [3] [4] [5] [6] . On the other hand, T H 17 cells also mediate the pathological immune responses involved in autoimmune conditions, such as multiple sclerosis, colitis, and even autism, and the prevention of these conditions depends on inhibiting the formation and function of T H 17 cells [7] [8] [9] [10] [11] [12] . The critical function of RORγt has been demonstrated by severe immune deficiency in both mice 13 and humans 14 carrying mutated versions of the RORγt-encoding gene Rorc. In addition, RORγt enhances thymocyte survival and is thus essential for thymic T cell development. RORγt is also required for the biogenesis of secondary lymph tissues, including gut-associated Peyer's patches [15] [16] [17] [18] . Because RORγt is required for the generation of pathogenic T H 17 cells responsible for autoimmunity, it is an attractive target for the development of drugs to control T H 17-mediated immunological disorders 19, 20 . It is thus important to understand the mechanisms regulating RORγt function.
As a member of the steroid nuclear receptor superfamily, RORγt has two conserved domains 21, 22 : an amino-terminal DNA-binding domain and a carboxyl-terminal ligand-binding domain. The very carboxyl terminal of the ligand-binding domain is an activation function 2 (AF2) motif responsible for recruiting steroid receptor coactivator 1 (SRC1) to nuclear receptors, which is required for RORγt-mediated transactivation of genes essential for T H 17 differentiation [23] [24] [25] . Because RORγt is a transcription factor, previous studies have focused on the transcriptional aspects of RORγt function. However, the post-translational mechanisms that regulate RORγt function have long been neglected.
Sumoylation is a type of post-translational modification in which small ubiquitin-related modifier (SUMO) proteins are covalently attached to the lysines of target proteins. Mammals usually express three SUMO proteins: SUMO1, SUMO2, and SUMO3, which share approximately 50% amino acid sequence identity. Sumoylation is a multi-step reaction that is sequentially catalyzed by a SUMO-activating E1 enzyme, the single conjugating E2 enzyme Ubc9, and an E3 ligase. Sumoylation controls many aspects of cellular function 26, 27 by regulating protein stability and by enabling new protein-protein interactions through the addition of new docking sites. Knockout of the E2 enzyme Ubc9 affects thymic T cell development and the expansion of regulatory T cells 28, 29 , implicating sumoylation as an important regulator of these two processes. However, the roles of sumoylation in other aspects of T cell development and function, including T H 17 differentiation, remain unknown.
Here, we demonstrate that the loss of Sumo3, but not Sumo1, impairs T H 17 differentiation and delays progression of thymic immature single-positive (ISP) CD8 + cells, which are similar to phenotypes observed in Rorγt −/− mice. This work leads us to identify lysine 31 (K31) as a functional sumoylation site in RORγt. We find that mice expressing K31-mutant RORγt K31R are incapable of being sumoylated at K31 and exhibit multiple defective RORγt-dependent functions, including differentiation of T H 17, induction of T H 17-dependent experimental autoimmune encephalomyelitis (EAE), the progression of thymic ISP, and development of Peyer's patches. Additional data attribute these effects to the defective recruitment of histone acetyltransferase KAT2A, which impairs the interactions between RORγt and coactivator SRC1. Finally, we identify the E3 ligase responsible for RORγt sumoylation to be PIAS (protein inhibitor of activated STAT) proteins form the largest family of sumoylation E3 ligases 30 , as the E3 ligase PIAS4 is able to bind and sumoylate RORγt at K31, and knockdown of PIAS4 impairs RORγt-dependent T H 17 differentiation and progression of ISP, phenocopying the effects observed in RORγt K31R/K31R mice. Our study thus reveals sumoylation as a novel post-translational mechanism for regulating RORγt-dependent functions.
Results
Sumo3, but not Sumo1, stimulates T H 17 differentiation. To investigate whether sumoylation plays a role in T helper cell differentiation, we examined the differentiation of Sumo1 −/− and Sumo3 -−/− CD4 + T lymphocytes (Sumo2 −/− mice are embryonic lethal 31 ). Deletion of Sumo1 compromised T H 1 and Treg differentiation, but did not affect T H 2 differentiation ( Supplementary  Fig. 1a) . Deletion of Sumo3, but not Sumo1, dramatically impaired T H 17 differentiation (Fig. 1a) and decreased expression of critical T H 17 genes (Fig. 1b) . However, Sumo3 −/− CD4 + T cells could normally differentiate into T H 1, T H 2, and Treg lineages ( Supplementary Fig. 1b ). We next adoptively transferred Sumo3 −/− CD4 + T cells into Rag1 −/− mice to test their ability to induce EAE. Rag1 −/− mice reconstituted with Sumo3 −/− CD4 + T cells had attenuated disease severity (Fig. 1c) , which correlated with lower infiltration of lymphocytes, including Ly6G + neutrophils, CD4 + T cells, and CD11b + Ly6C + monocytes, into the central nervous system (CNS; Fig. 1d and Supplementary Fig.1c for gating strategy). In addition, the percentages (Supplementary Fig.1d ) and numbers ( Fig. 1e ) of CNS-infiltrating IL-17A + , IFNγ + , GM-CSF + , IL-17A + IFNγ + , and IL-17A + GM-CSF + CD4 + T cells responsible for EAE were also significantly lower in these mice [7] [8] [9] . These results suggest that SUMO3, but not SUMO1, promotes RORγt-dependent T H 17 differentiation.
Sumo3, but not Sumo1, is required for thymic ISP progression. To determine whether sumoylation plays a role in RORγt-dependent thymocyte development, we analyzed thymocytes from Sumo3 −/− and Sumo1 −/− mice. The thymic cellularity of Sumo1 −/− (Fig. 2a) and Sumo3 −/− (Fig. 2b) mice was equivalent to that of wild-type (WT) mice. We then analyzed CD4 and CD8 markers to monitor the three sequential stages of thymocyte development: CD4 − CD8 − double-negative (DN), CD4 + CD8 + double-positive (DP), and CD4 + or CD8 + single-positive (SP). We did not detect obvious differences in the overall percentages of DN, DP, and SP populations in the thymi of WT versus Sumo1 −/− mice (Fig. 2c) . We did, however, notice an increased percentage of CD8 + SP cells in the thymi of Sumo3 −/− mice (Fig. 2d) . Further scrutiny of the CD8 + SP population revealed a significantly greater percentage of immature TCR lo CD24 hi CD8 + cells (ISPs), as well as a correspondingly lower percentage of mature TCR hi CD24 lo CD8 + cells, in the thymi of Sumo3 −/− (Fig. 2e ), but not Sumo1 −/− (Fig. 2f) , mice. These findings indicate the selective function of Sumo3 in the progression of ISP, which is RORγt-dependent 18 . Furthermore, whereas the absolute number of ISPs was increased in Sumo3 −/− compared to WT thymi ( Supplementary Fig. 1e ), there was no difference in the number of mature TCR hi CD24 lo CD8 + cells in WT and Sumo3 −/− thymi, suggesting that the overall increase in CD8 + SP cells observed in Sumo3 −/− thymi is due to increased ISPs and not mature CD8 + cells. To determine the intrinsic function of SUMO3 in thymocyte development, we isolated and co-cultured CD4 − CD8 − DN thymocytes with OP9-DL4 stroma cells to observe their differentiation in vitro 32 (Fig. 2g) . Although both WT and Sumo3 −/− DN cells could differentiate into DP and SP populations, there were increased percentages and numbers of CD8 + SP but not CD4 + SP cells in Sumo3 −/− cultures (Fig. 2g , top panels). Furthermore, we detected significantly more TCR lo CD24 hi CD8 + ISPs among Sumo3 −/− CD8 + cells than among WT CD8 + cells (Fig. 2g, bottom panels) , suggesting the (Fig. 3a , second panel). To identify the sumoylated residues, immunoprecipitated RORγt was subject to mass spectrometric analysis to detect a signature peptide containing a "QTGG" remnant at the sumoylation site. Lysines 11 and 31 (K11 and K31) were identified as the sumoylation sites in RORγt ( Supplementary Fig. 2a ). To confirm these sites, K11 and K31 were mutated to arginine to prevent the sumoylation, and sumoylation of purified WT and mutant RORγt was compared in vitro (Fig. 3b) . As expected, we observed that SUMO3-RORγt could not be detected in the absence of the E2 enzyme Ubc9 or SUMO3. We also observed that, whereas the K11R mutation (RORγt K11R ) did not affect SUMO3-RORγt levels, the K31R mutation (RORγt K11R ) greatly reduced SUMO3-RORγt (Fig. 3b) . In contrast, we could not detect obvious SUMO1-modified RORγt, RORγt K11R , or RORγt K31R (Fig. 3c) . These results strongly suggest that RORγt is SUMO3-but not SUMO1-modified at K31. Interestingly, sequence alignment indicated that K31 and its surrounding amino acid sequence are highly conserved in RORγt across species ( Supplementary  Fig. 2b ), suggesting the importance of K31 as a sumoylation site.
To determine the role of K31 sumoylation in RORγt-dependent functions, we compared the ability of retrovirally expressed RORγt and RORγt K31R to rescue T H 17 differentiation in Rorγt −/− CD4 + T cells (Fig. 3d) . As expected, Rorγt −/− CD4 + T cells transduced with retroviruses expressing GFP alone (empty virus, EV) failed to differentiate into T H 17 cells. T H 17 cell differentiation was rescued by WT RORγt and RORγt K11R , but not RORγt K31R (Fig. 3d , and Supplementary Fig. 2c for gating strategy), although both mutants were expressed at the levels comparable to WT RORγt expression (Fig. 3e) . Consistent with these results, the expression of critical T H 17 genes was lower in RORγt K31R -reconstituted Rorγt −/− T cells than in WT RORγt-reconstituted T cells (Fig. 3f ), confirming that the T H 17 differentiation program is impaired when K31 sumoylation is blocked.
To determine whether K31 sumoylation is essential for RORγt-regulated thymocyte development, we compared the development of Rorγt −/− thymocytes retrovirally reconstituted with RORγt, RORγt K11R , and RORγt K31R in vitro (Fig. 3g , and Supplementary  Fig. 2d for gating strategy). Isolated Rorγt −/− CD4 − CD8 − DN thymocytes transduced with retroviruses simultaneously expressing GFP and RORγt or RORγt K11R , but not expressing GFP alone (EV), differentiated into CD4 + CD8 + DP and CD4 + SP cells. However, retroviral expression of RORγt K31R failed to fully restore thymocyte development, indicated by more CD4 − CD8 − DN and CD8 + SP cells and fewer CD4 + CD8 + DP and CD4 + SP cells (Fig. 3g) . Interestingly, the expression of surface CD4, which is lower in Rorγt −/− thymocytes than in WT thymocytes 18 , was rescued in Rorγt −/− cells reconstituted with WT RORγt or RORγt K11R but not with RORγt K31R (Fig. 3h) , suggesting a role of K31 sumoylation in the regulation of CD4 expression. Altogether, these data demonstrate that blocking sumoylation at K31 impairs RORγt functions in thymocyte development and T H 17 differentiation in vitro.
RORγt K31R/K31R mice exhibit defective T H 17 differentiation. To investigate the function of K31 sumoylation in vivo, we generated a strain of mouse expressing RORγt K31R (RORγt K31R/K31R ) ( Supplementary Fig. 3a-3c ). The number of splenocytes was slightly higher in RORγ tK31R/K31R mice than in WT mice, which was partially attributed to increased CD8 + but not CD4 + T cells ( Supplementary Fig. 4a ). T cells from RORγt K31R/K31R mice consistently exhibited defective T H 17 differentiation, as indicated by the lower generation of IL-17A + cells compared to WT mice ( Fig. 4a) and decreased expression of critical T H 17 genes (Supplementary Fig. 4b ). However, the T cells from RORγt K31R/K31R mice differentiated into T H 1, T H 2, and Treg comparably to T cells from WT mice ( Supplementary Fig. 4c ), suggesting a selective defect in differentiation into T H 17 cells. The observed reduction in T H 17 differentiation was not due to decreased expression of RORγt K31R , which was comparable with WT RORγt expression in T H 17 cells (Fig. 4b) . To confirm that K31R mutation affects the sumoylation of RORγt in vivo, we compared levels of SUMO3-RORγt in differentiated T H 17 cells from WT and RORγt K31R/K31R mice. Indeed, SUMO3-modified (Fig. 4c) , but not ubiquitinmodified ( Supplementary Fig. 4d ), RORγt was significantly reduced in RORγt K31R T H 17 cells, confirming that RORγt-K31 is sumoylated in vivo.
To assess the global effects of K31 sumoylation on T H 17 differentiation, we mapped RORγt DNA-binding sites using ChIP-seq and gene expression profiles using RNA-seq in WT and RORγt K31R/K31R T H 17 cells. We found similar expression patterns in biological replicates of WT and RORγt K31R/K31R T H 17 cells, as 
Representative flow cytometric analysis of CD4 and CD8 on the surface of thymocytes from WT and c Sumo1 −/− or d Sumo3 −/− mice (top two panels). The bottom panels present the absolute numbers of CD4 + , CD8 + , CD4 − CD8 − , and CD4 + CD8 + thymocytes for individual mice (n = 5 per genotype). e, f Representative flow cytometric analysis of CD24 and TCRβ expression in CD8 + cells of WT and e Sumo3 −/− or f Sumo1 −/− thymi (two panels on the left). The two panels on right present the percentages of immature TCR lo CD24 hi ISPs and mature TCR hi CD24 lo cells in the thymi of individual mice (n = 5 per genotype). g Representative flow cytometric analysis of CD4 and CD8 expression in cells differentiated from sorted WT and Sumo3 −/− CD4 -CD8 − thymocytes co-cultured for 3 d with OP9-DL4 stroma cells and IL-7 (5 ng/ml) to assess ex vivo thymocyte development (top two panels on the left). The top two panels on the right present the percentages of CD4 + and CD8 + cells differentiated from individual mice (n = 5 per genotype). The bottom two panels on the left show flow cytometric analysis of CD24 and TCRβ expression in CD8 + cells from the top panels. The bottom two panels on the right present the percentages of immature TCR lo CD24 hi ISPs and mature TCR hi CD24 lo thymocytes from individual mice (n = 5 per genotype). NS, not significant (P > 0.05); *P < 0.05 (t-test); **P < 0.01 (t-test). Data are from three experiments (a, b; c, d, four bottom panels; e-g, two right panels; presented as median [ indicated by the heat map in Fig. 4d showing similarly up and downregulated genes. Many T H 17 genes, including Il17a, Il17f, Ccl20, Csf2, Ccr6, and Il1r1, but not Rorc, were down-regulated in RORγt K31R/K31R T H 17 cells (Fig. 4e) , suggesting an essential function of RORγt K31 sumoylation in the expression of genes critical for T H 17 differentiation. ChIP-seq analysis identified DNA-binding peaks within critical T H 17 gene loci, including Il17a and Il17f, which overlap well with our previously identified RORγt DNA-binding peaks ( Supplementary Fig. 4e ) 33 . Furthermore, we conducted a search among all the RORγt DNA-binding (Fig. 5d) , which was associated with lower CNS infiltration by various mononuclear lymphocytes ( Supplementary Fig. 5a ) and lower expression of critical T H 17 genes in lymphocytes recovered from the CNS (Supplementary Fig. 5b ). In contrast, RORγt K31R/K31R and WT T cells stimulated under T H 1 conditions did not differentially induce EAE in Rag1 −/− mice (Fig. 5e ), which was demonstrated by mostly comparable numbers of various CNS-infiltrating mononuclear lymphocytes ( Supplementary Fig. 5c ). These results indicate that sumoylation at K31 is required selectively for RORγt-dependent T H 17 immunity in vivo.
ISPs accumulate in thymi of RORγt K31R/K31R mice. To determine the function of K31 RORγt sumoylation in thymocyte development, we analyzed thymocytes from WT, RORγt −/− , and RORγt K31R/K31R mice. The expression of RORγt K31R and WT RORγt was equivalent in CD4 + CD8 + thymocytes (Fig. 6a , top panel) and non-detectable in CD4 + SP cells (Fig.6a , bottom panel), suggesting that K31R does not disturb the expression pattern of RORγt. However, SUMO3-modified ( Supplementary  Fig. 6a ), but not ubiquitinated (Supplementary 6b), RORγt was lower in RORγt K31R/K31R thymocytes compared to those of WT thymocytes, confirming K31 as an RORγt sumoylation site in thymocytes. RORγt is known to regulate the survival and cell cycle of thymocytes by upregulating the expression of Bcl-x L 18 . However, WT and RORγt K31R/K31R mice had comparable thymocyte survival ( Supplementary Fig. 6c ) and percentages of cells with > 2 N of DNA (in the DNA synthesis phase) ( Supplementary  Fig. 6d ). In addition, RORγt K31R/K31R mice had lower rather than greater thymic cellularity that WT mice (Fig. 6b) . These results suggest that K31 sumoylation is dispensable for RORγt-dependent thymocyte survival and cell cycle regulation. Analysis of the surface markers CD4 and CD8 revealed greater percentages of CD4 − CD8 − DN and CD8 + SP cells in RORγt K31R/ K31R thymi than in WT thymi, similar to those observed in Rorγt −/− thymi (Fig. 6c , three panels on the left, and Supplementary Fig. 6e ). In addition, the absolute number of CD8 + SP but not CD4 + SP cells (Fig. 6c , two panels on right) was greater in RORγt K31R/K31R thymi than in WT. Among CD8 + SP cells, there was a higher frequency of immature TCR lo CD24 hi CD8 + cells (ISPs) in RORγt K31R/K31R thymi, similar to the frequency in Rorγt −/− thymi (Fig. 6d) , as well as Sumo3 −/− thymi (Fig. 2e) . Not only the frequency but the absolute number of ISPs was greater in RORγt K31R/K31R thymi compared to WT thymi, whereas the cellularity of mature TCR hi CD24 lo CD8 + cells was comparable between groups ( Supplementary Fig. 6f ). These results indicate the critical function of RORγt-K31 sumoylation in the progression of ISPs. In addition, we observed lower levels of surface CD4 on CD4 + CD8 + DP cells in both RORγt K31R/K31R and Rorγt −/− thymi compared to WT thymi (Fig. 6e) , suggesting a positive role of RORγt-K31 sumoylation in CD4 expression. We next compared the differentiation of sorted WT and RORγt K31R/ K31R CD4 − CD8 − DN thymic cells co-cultured with stroma cells in vitro (Fig. 6f) . As expected, DN cells derived from RORγt K31R/K31R mice gave rise to a higher frequency of CD8 + SP cells and a greater percentage of TCR lo CD24 hi CD8 + ISPs than DN cells from WT mice. We thus separated the functions of RORγt in thymocyte development into two categories: (1) K31 sumoylation-independent functions, including survival and cell cycle, and 2) K31 sumoylation-dependent functions, including the progression of ISPs and CD4 expression.
To better understand the K31 sumoylation-dependent and -independent functions of RORγt, we mapped the landscape of RORγt DNA-binding sites and examined the gene expression profiles of WT and RORγt K31R/K31R thymocytes using ChIP-seq Fig. 6g , which demonstrates the reproducibility of our RNA-seq assay. We previously showed that the reduced survival and dysregulated cell cycle of Rorγt −/− thymocytes were associated with significant changes in the expression of several important cell survival and cell cycle regulators 33 . The expression of several of these regulators, Pik3r3, Wee1, Bcl2, Myc, and Bcl2l1, was not significantly different between WT and RORγt K31R/K31R thymocytes (Fig. 6h , genes listed on the left in orange). Therefore, K31 sumoylation does not appear to be required for the expression of these critical survival and cell cycle regulators, which explains why thymocyte survival and cell cycle regulation are K31 sumoylation-independent. However, we identified several genes, including Rasgrp1, Ets2, Cd6, Ptcra, Rasgrp4, and Cd4, that were downregulated in RORγt K31R/K31R thymocytes compared to WT thymocytes (Fig. 6h , genes listed on the right in red) and are known to regulate thymocyte development [35] [36] [37] [38] . We found that the CD4 − encoding Cd4 gene was downregulated in RORγt K31R/K31R thymocytes compared to WT thymocytes (Fig. 6h , top gene in red), which is consistent with lower protein levels of CD4 on RORγt K31R/K31R thymocytes (Fig. 6e) , as well as Rorγt −/− thymocytes retrovirally reconstituted with RORγt K31R (Fig. 3h) . In particular, Cd6 was reported to regulate the progression of ISPs 35 . Therefore, we have demonstrated that RORγt K31 sumoylation is required for the transactivation of these genes, which are likely responsible for K31 sumoylationdependent functions, such as the progression of ISPs. Our ChIPseq assay also identified obvious RORγt DNA-binding peaks at Bcl2l1 (Fig. 6i, j) , Cd6, Ets2, Rasgrp1, and Cd4 loci ( Supplementary  Fig. 6g ), suggesting that they are direct targets of RORγt. Interestingly, RORγt K31R binds to the same sites on these gene loci as WT RORγt, suggesting that K31 sumoylation is not required for the DNA binding of RORγt. Therefore, K31 sumoylation of RORγt likely regulates the expression of these target genes through DNA binding-independent mechanisms. RORγt is required for the development of secondary lymph tissues 18 . To determine the roles of K31 sumoylation in RORγt-dependent organogenesis, we examined lymph tissues in RORγt K31R/K31R and WT mice. RORγt K31R/K31R mice had all the lymph nodes observed in WT mice except for Peyer's patches ( Supplementary Fig. 6h ), suggesting a selective role of K31 sumoylation in the biogenesis of Peyer's patches.
Sumoylation stabilizes RORγt-KAT2A-SRC1 complexes. One function of sumoylation is to regulate protein stability 39 . However, this does not seem to be the case for K31 sumoylation of RORγt, as the protein levels of RORγt and RORγt K31R in both T H 17 cells (Fig. 4b) and thymocytes (Fig. 6a) were equivalent and the degradation rates of RORγt and RORγt K31R were comparable ( Supplementary Fig. 7a ). Given that sumoylation can also regulate protein-protein interactions by adding a new docking site, we tested whether K31 sumoylation regulated the binding of RORγt to its co-factors. RORγt is known to interact with co-activator SRC1 to regulate T H 17 differentiation 25 . Indeed, we found that RORγt K31R , compared to WT RORγt and the controls RORγt K11R and RORγt K69R , had impaired interactions with SRC1 (Fig. 7a) . This finding was supported by the lower detection of endogenous RORγt K31R -SRC1 complexes in RORγt K31R/K31R T H 17 cells (Fig. 7b, left panel) and thymocytes (Fig. 7b, right panel) compared to their WT counterparts. Furthermore, our ChIP-seq assay showed that the recruitment of SRC1 to the Il17a and Il17f loci by RORγt K31R was much less than that by WT RORγt in T H 17 cells (Fig. 7c) , again confirming reduced RORγt K31R -SRC1 interactions compared to RORγt-SRC1 interactions.
We found in the literature a report that KAT2A (or GCN5), a histone acetyltransferase, is able to synergize with SRC1 to bind to nuclear receptors 40 . Furthermore, using mass spectrometry, we identified with high confidence that KAT2A and SRC1 are RORγt-binding proteins in both thymocytes and T H 17 cells (Supplementary Fig. 7b ). Indeed, in HEK293T cells, we detected the RORγt-KAT2A interaction, which was further enhanced by the addition of SUMO3 and Ubc9. In contrast, the RORγt K31R -KAT2A interaction was much weaker and was not affected by SUMO3 and Ubc9 (Fig. 7d) . These results suggest that the sumoylation of K31 promotes the interaction between RORγt and KAT2A. Furthermore, we found that the expression of KAT2A enhanced the RORγt-SRC1 interaction in HEK293T cells (Fig. 7e) . On the other hand, knockdown of endogenous KAT2A greatly impaired the RORγt-SRC1 interaction in T H 17 cells (Fig. 7f) , suggesting that KAT2A promotes the RORγt-SRC1 interaction. In addition, immunoprecipitation of RORγt K31R brought down much less KAT2A and SRC1 compared to immunoprecipitation of WT RORγt in both T H 17 cells (Fig. 7b , left panel) and thymocytes (Fig. 7b, right panel) , suggesting an essential role of K31 sumoylation in the formation of stable RORγt-KAT2A-SRC1 complexes. RORγt and SRC1 have already been established as essential for T H 17 differentiation 13,25 , we thus aimed to determine the function of KAT2A in T H 17 differentiation using a knockdown approach. We found that the knockdown of KAT2A (Supplementary Fig. 7c ) impaired T H 17 differentiation (Fig. 7g) and decreased expression of critical T H 17 genes (Supplementary Fig. 7d ). Of the two short hairpin RNAs used into knockdown KAT2A (shKAT2A-1 and shKAT2A-2), shKAT2A-2 inhibited T H 17 differentiation more potently, which correlated with its higher potency in repressing KAT2A expression ( Supplementary Fig. 7c ), demonstrating an essential 
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Fig. 5 RORγt K31R/K31R mice are resistant to induction of EAE. a Mean clinical EAE scores of female WT and RORγt K31R/K31R mice (n = 10 per genotype) from days 0 to 30 after immunization with the EAE-inducing epitope MOG . b Quantification of CNS-infiltrating cells from WT and RORγt K31R/K31R mice in which EAE was induced (same as in a) expressing characteristic mononuclear cell surface markers, assessed using flow cytometry at the peak of disease. c qPCR analysis of cytokine-encoding Il17a (top left), Il17f (top middle), Ifng (top right), Csf2 (bottom left), Il22 (bottom middle) and Ccl20 (bottom right) mRNA in the CNS-infiltrating lymphocytes assessed in a. Expression is presented relative to that of the control gene Actb. 
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WT PIAS4 catalyzes the K31 sumoylation of RORγt. PIAS proteins form the largest family of sumoylating E3 ligases 30 . To identify the E3 responsible for RORγt sumoylation, we first monitored the interactions between RORγt and individual PIAS proteins (Fig. 8a) . We could not detect interactions between RORγt and PIAS2 or PIAS3. However, we detected a weak PIAS1-RORγt interaction and a strong PIAS4-RORγt interaction. We next sought to determine whether PIAS1 and PIAS4 could sumoylate RORγt at K31. For this purpose, we mutated all lysines of RORγt except K31 to arginines (RORγt-K31) so that only K31 could be sumoylated. Whereas we detected a relatively low amount of SUMO3-modified RORγt-K31 in the presence of PIAS1, we detected a much stronger SUMO3-modified RORγt-K31 signal in the presence of PIAS4 (Fig. 8b) . As expected, we could barely detected any SUMO1-modified RORγt-K31 in the presence of PIAS1 or PIAS4 (Supplementary Fig. 8a ), suggesting that PIAS4 and to a lesser extent PIAS1 can catalyze the addition of SUMO3, but not SUMO1, to K31 of RORγt.
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To further evaluate the role of PIAS4 in regulating RORγt-dependent functions, we assessed the effects of PIAS4 knockdown on T H 17 differentiation and thymocyte development in vitro. Knockdown of PIAS4 ( Supplementary Fig. 8b ) resulted in impaired T H 17 differentiation (Fig. 8c) and reduced expression of important T H 17 signature genes (Fig. 8d) . However, knockdown of PIAS1 ( Supplementary Fig. 8b ) did not affect T H 17 differentiation, which is consistent with a report that PIAS1 is not required for T H 17 differentiation 41 . We next monitored the in vitro differentiation of sorted CD4 -CD8 − thymocytes when PIAS1 or PIAS4 was knocked down. Knockdown of PIAS4 led to a slightly increased percentage of CD8 + SP cells (Fig. 8e, top  panels) . More importantly, there was a dramatically greater percentage of TCR lo CD24 hi CD8 + ISPs, and a correspondingly lower percentage of TCRβ lo CD24 hi CD8 + cells, among CD8 + SP cells in the cells with PIAS4 knocked down (Fig. 8e, bottom  panels) . In contrast, the knockdown of PIAS1 had no effect on the percentage of TCRβ lo CD24 hi CD8 + ISPs (Supplementary Fig. 8d) . Therefore, the knockdown of PIAS4 impaired T H 17 differentiation and increased ISPs, which were both phenotypes observed in Sumo3 −/− and RORγt K31R/K31R mice. Taken together, these data suggest that PIAS4 catalyzes the addition of SUMO3 to K31 of RORγt and thus regulates RORγt-dependent T H 17 differentiation and progression of ISPs.
Discussion
RORγt controls the function of T H 17 cells, which mediate both protective and pathogenic immunity. However, little is known about the post-translational mechanisms that regulate RORγt function. Our in vitro and in vivo results demonstrate that sumoylation of RORγt is a novel regulatory mechanism for controlling RORγt-dependent T H 17 immunity, thymic ISP progression, and development of Peyer's patches: (1) Sumo3 −/− but not Sumo1 −/− mice display defects in RORγt-regulated T H 17 differentiation and thymocyte development (specifically, they accumulate ISPs); (2) RORγt is SUMO3-but not SUMO1-modified at K31 in both T H 17 cells and thymocytes; (3) mice expressing RORγt K31R exhibit multiple defective RORγt-dependent functions, including differentiation of T H 17 cells, induction of T H 17-mediated EAE, progression of ISPs in the thymus, and development of Peyer's patches. We also identified PIAS4 as the E3 that catalyzes K31 sumoylation and regulates T H 17 differentiation and progression of thymic ISPs. Therefore, we have demonstrated that post-translational sumoylation is a novel mechanism for modulating RORγt-dependent T H 17 immunity that can be targeted by clinical therapies to enhance protective and inhibit pathogenic T H 17 immunity.
Previous studies have reported that RORγt function is regulated by ubiquitination, which is a post-translational modification similar to but distinct from sumoylation 42, 43 . The ubiquitin E3 ligase, Itch, was found to bind and ubiquitinate RORγt for degradation and thus regulate T H 17-dependent immune responses 43 , which explains why Itch −/− mice develop colitis. Another E3 ligase, UBR5, was also reported to regulate RORγt stability through the ubiquitin pathway 42 . However, the RORγt ubiquitination sites involved in the above two studies remain unknown. Meanwhile, we identified lysines 446 and 69 as ubiquitination sites through which RORγt-dependent T H 17 differentiation can be controlled via degradation-independent mechanisms 33, 44 . Therefore, we and others have demonstrated that T H 17 immunity can be controlled through the ubiquitin pathway, which regulates RORγt stability and protein interactions. Although sumoylation can also regulate protein stability, our results do not support that K31 sumoylation affects RORγt stability. We showed that K31 sumoylation stimulates the recruitment of histone acetyltransferase KAT2A and co-activator SRC1 to RORγt. In addition, we showed that preventing K31 sumoylation reduces recruitment of SRC1 to the Il17f locus, suggesting that K31 sumoylation regulates the interaction between RORγt and its co-factors to activate Il17f expression.
RORγt has long been known to regulate thymocyte development 18 . However, RORγt chromatin occupancy and target genes panels on left) . The two panels on the right present the numbers of CD4 + and CD8 + cells among thymocytes from individual mice (n = 5). d Flow cytometric analysis of CD24 and TCRβ expression among CD8 + cells shown in (c) (three panels on left). The two panels on the right present the frequency of indicated cells among the thymocytes (n = 5). e Flow cytometric analysis of CD4 levels among CD4 + CD8 + thymocytes. f Flow cytometric analysis of CD4 and CD8 expression on in vitro differentiated thymocytes of the indicated mice (top two panels on the left). The top three panels on the right present the percentages of indicated cells differentiated in vitro (n = 5). The bottom panels on the left present the cytometric analysis of CD24 and TCRβ expression in the CD8 + subpopulation from the top panels. The bottom two panels on the right present the percentages of indicated thymocytes among the CD8 + cells (n = 6). g RNA-seq analysis of genes upregulated (red) or downregulated (blue) in thymocytes of the indicated mice assessed in f. Two biological replicates each genotype. h Comparison of the gene expression profile of the thymocytes assessed in g. The colors indicate downregulated (red) or comparably expressed genes (orange) in RORγt K31R/K31R compared to WT thymocytes. i ChIP-seq analysis identified RORγt DNA-binding peaks (arrows) inBcl2l1 in the cells assessed in g (two biological replicates). j ChIP-qPCR analysis of RORγt binding toBcl2l1 in the thymocytes assessed in f. NS, not significant (P > 0.05); **P < 0.01 (ttest). Data are from three experiments (b; c, d, two panels on the right; f, right panels; j; presented as median [central line], maximum and minimum [box ends], and outliers [extended lines]), are pooled from two biological replicates (g, h), or are one representative of three independent experiments (a; c, d, left; e; i) in thymocytes were not known, which limited understanding of the mechanisms responsible for RORγt-regulated thymocyte development. To address this need, we mapped genome-wide RORγt DNA-binding sites and identified RORγt target genes. Furthermore, we identified K31 as the sumoylation site of RORγt, which enabled us for the first time to dissect RORγt functions in thymus. One important function of RORγt is to regulate thymocyte survival by up-regulating anti-apoptotic Bcl-x L expression 18 . Our results showed that K31 sumoylation is actually not required to up-regulate Bcl-x L or to maintain thymocyte survival; however, it is specifically required for the progression of thymic ISPs. Our study thus separates RORγt functions and establishes a link between RORγt-regulated functions and RORγt target genes. T H 17 cells produce the effector cytokines IL-17A, IL-17F, IL-22, and GM-CSF to mediate pathological inflammation responsible for many types of autoimmune diseases; targeting T H 17 cells is thus a potential treatment for these diseases 45 . Indeed, inhibiting the T H 17 pathway is effective for treating psoriasis and multiple sclerosis 46, 47 . Considering the essential function of RORγt in T H 17 cells, pharmaceutical and academic scientists are developing RORγt inhibitors to treat T H 17-dependent autoimmunity 11, 19, 20, 48, 49 . Unfortunately, such RORγt inhibitors can induce thymic lymphoma by inhibiting RORγt during thymocyte development 50 . Although K31 sumoylation is required for the progression of thymic ISP, it is not essential for regulating thymocyte survival or cell cycle progression, which are most likely responsible for the development of lymphoma observed in RORγt −/− mice 50, 51 . Therefore, we expect that drugs targeting the K31 sumoylation pathway will inhibit T H 17-mediated pathological immunity without interfering with thymocyte survival or cell cycle regulation, which could induce lymphoma in patients. Therefore, in addition to revealing a novel post-translational modification-based mechanism for regulating RORγt-dependent T cell function, our results also facilitate the development of a new category of RORγt-based drugs to treat T H 17-mediated autoimmunity without serious side effects.
Methods
Mice. Both the targeting vector and the knock-in RORγt K31R/K31R mice were designed and generated by Biocytogen LLC. RORγt K31R/K31R mice are available at The Jackson Laboratory as Stock No. 032604. Rag1 −/− (002216) mice were purchased from the Jackson Laboratory. The Rorγt −/− (RORC2 −/− ) 18 , Sumo1 −/−52 , and Sumo3 −/− mice 31 were bred and housed under specific pathogen-free (SPF) conditions in the Animal Resource Center at the Beckman Research Institute of City of Hope under protocols approved by the Institutional Animal Care and Use Committee. Mice were 10-12 weeks of age for EAE studies and 6-8 weeks of age for all other experiments, with littermates age-matched across experimental groups.
Plasmids. cDNA encoding RORγt or SRC1 was inserted into a XhoI/EcoRI-cut pMSCV vector 44 . Point mutations of RORγt were generated using a site-directed mutagenesis kit from Agilent Technologies. pRK5-HA-ubiquitin (a gift from Ted Dawson at Johns Hopkins University School of Medicine; #17603-17608), pCMVsport2-mGCN5 (a gift from Sharon Dent at MD Anderson Cancer Center; #23098), and constructs for expressing FLAG-PIAS (gifts from Ke Shuai at the University of California Los Angeles; #15206-15210) were obtained from Addgene. pCMV-FLAG-SUMO1, pCMV-FLAG-SUMO3, and pcDNA-UBC9 were generous gifts from Yuan Chen at the City of Hope. The LMP vector-based retroviral short hairpin RNA (shRNA)-expressing vectors were constructed using following oligonucleotide sequences: shKAT2A-1: TGCTGTTGAC AGTGAGCGACCGCTATCTGGGCTACATCAATAGTGAAGCCACAGATGTA TTGATGTAGCCCAGATAGCGGCTGCCTACTGCCTCGGA; shKAT2A-2: TGCTGTTGACAGTGAGCGCGCCAAGAATGCCCAAGGAATATAGTGAAG CCACAGATGTATATTCCTTGGGCATTCTTGGCATGCCTACTGCCTCGGA; shPIAS1-1: TGCTGTTGACAGTGAGCGAGGAACTAAAGCAAATGGTTATTA GTGAAGCCACAGATGTAATAACCATTTGCTTTAGTTCCGTGCCTACT GCCTCGGA; shPIAS1-2: TGCTGTTGACAGTGAGCGCCCGGATCATTCTAG AGCTTTATAGTGAAGCCACAGATGTATAAAGCTCTAGAATGATCCGGA TGCCTACTGCCTCGGA; shPIAS4 − 1: TGCTGTTGACAGTGAGCGCGCTACA GAGGTTGAAGACGATTAGTGAAGCCACAGATGTAATCGTCTTCAA CCTCTGTAGCATGCCTACTGCCTCGGA; shPIAS4-2: TGCTGTTGACAG TGAGCGCGAGCTGTATGAGACTCGCTATTAGTGAAGCCACAGATGTAAT AGCGAGTCTCATACAGCTCTTGCCTACTGCCTCGGA.
Retrovirus transduction. Platinum-E packaging cells (Cell Biolabs) were plated in a 10-cm dish in 10 ml RPMI-1640 medium plus 10% FBS. 24 h later, cells were transfected with empty pMSCV or pLMP vectors or the appropriate retroviral expression plasmids with BioT transfection reagent (Bioland). After overnight incubation, the medium was replaced and cultures were maintained for another 24 h. Viral supernatants were collected 48 and 72 h later, passed through 0.4-μm filters (Millipore), and supplemented with 8 µg/ml of polybrene (Sigma-Aldrich) and 100 U/ml of recombinant IL-2 (for transducing CD4 + T cells) or 5 ng/ml of recombinant IL-7 (for transducing CD4 -CD8 − thymocytes). Naïve CD4 + T cells were first activated with 0.25 µg/ml hamster anti-CD3 (145-2C11; Biolegend) and 1 µg/ ml hamster anti-CD28 (37.51; Biolegend) in 24 − well plates pre-coated with 0.2 mg/ ml goat anti-hamster antibody for 24 h, then spin-infected with viral supernatants (1200 g, 30°C for 2 h). The retroviral supernatant was also used to infect CD4 − CD8 − thymocytes that had been co-cultured with feeder OP9-DL4 cells (a generous gift from Ellen Rothenberg at Caltech) in the presence of recombinant IL-7 (5 ng/ml) for 24 h. After spin infection, the viral supernatant was replaced with culture media containing polarizing cytokines for in vitro differentiation (for transduced CD + T cells) or 5 ng/ml of recombinant IL-7 for in vitro T cell development (for transduced CD4 − CD8 − thymocytes), as described below.
In vitro differentiation. Naïve CD4 + T cells were purified from C57BL/6, RORγt −/− , or RORγt K31R/K31R mice by negative selection (Miltenyi Biotec). Suspensions of 4 × 10 5 cells/ml Iscove's modified DMEM (Cellgro) containing 2 mM L-glutamine, 50 mM 2-ME, 100 U/ml penicillin, 100 mg/ml streptomycin, and 10% FBS were cultured in 24-well plates pre-coated with 0.2 mg/ml goat anti-hamster antibody for three days. The medium was supplemented with 0.25 µg/ml hamster anti-CD3, 1 µg/ml hamster anti-CD28, and polarizing cytokines: 2 ng/ml TGF-β, 20 ng/ml IL-6, 5 µg/ml anti-IL-4, and 5 µg/ml anti-IFNγ for T H 17 differentiation; 20 µg/ml IL-12 and 5 µg/ml anti-IL-4 for Th1 differentiation; 10 ng/ml IL-4 and 10 µg/ml anti-IFNγ for T H 2 differentiation; or 5 ng/ml TGF-β for Treg differentiation. For analysis, cells obtained from in vitro cultures were incubated for 4-5 h with 50 ng/ml PMA (Sigma-Aldrich), 750 ng/ml ionomycin (Sigma-Aldrich), and 10 µg/ml brefeldin A (BD Biosciences) in a tissue culture incubator at 37°C, followed by intracellular cytokine staining. In vitro T cell development. Thymocytes were stained with 7-AAD and antibodies against Thy1.2, CD4, and CD8. Specific 7-AAD − Thy1.2 + CD4 − CD8 − populations were sorted using a FACSAria (BD Biosciences) and cultured at 5 × 10 5 /ml overnight on an 80% confluent OP9-DL4 monolayer in flat-bottom 24-well culture plates with αMEM (MEM α medium; Invitrogen Life Technologies) supplemented with 20% FBS, 100 U/ml penicillin-streptomycin, 2 mM L-glutamine (Invitrogen Life Technologies), and 5 ng/ml recombinant murine IL-7. After 72 h, co-cultures were harvested for flow cytometry analysis.
Flow cytometry. Mouse thymi or spleens were homogenized by crushing with the head of a 1-ml syringe in a petri dish, followed by straining through a 40-μm nylon filter. Red Blood Cell Lysing buffer (Sigma-Aldrich) was used for red cell lysis. Cells isolated from thymi or spleens, co-cultures harvested from in vitro development, and CD4 + T cells stimulated appropriately were stained for surface markers. Intracellular cytokines were stained with Fixation/Permeabilization solution (BD Cytofix/Cytoperm Kit; BD Biosciences). The expression of surface and intracellular markers were analyzed with FACSCanto (BD).
RNA sequencing and analysis. To measure gene expression in the thymi of WT or RORγt K31R/K31R mice, two separate samples were collected on different days, and thymocytes from four (two male and two female) were pooled each day. To determine the gene expression profile of T H 17 cells, naive CD4 + T cells were enriched from WT or RORγt K31R/K31R mice and polarized under T H 17 conditions for three days. Cells were processed for RNA isolation (Qiagen). Quality verification, library preparation, and sequencing were performed at the City of Hope Integrative Genomics Core Facility. Eluted RNAs were prepared for sequencing using Illumina protocols and sequenced on an Illumina HiSeq 2500 to generate 51-bp reads. Sequenced reads were aligned to the mouse mm10 reference genome using TopHat. Gene expression levels were quantified using HTSeq, and edgeR was utilized to identify differentially expressed genes (fold-change > 1.5 and FDR < 0.05). Gene expression abundance was quantified as fragments per kilobase of transcript per million fragments mapped (FPKM). Heat maps of differentially expressed genes were made with gplots using log2-transformed FPKM values.
Chromatin immunoprecipitation and DNA sequencing (ChIP-seq). A total of 2 × 10 7 cells were incubated with 1% formaldehyde to cross-link proteins with chromatin for 5 min at room temperature. 125 mM glycine was added to stop the cross-linking reaction. To shear genomic DNA into 200-500-bp fragments, cell lysates were sonicated using a water-bath sonicator (Covaris S200). Cell lysates were centrifuged (12,000 × g, 10 min) and incubated with specific antibodies (antiRORγt from D. Littman or anti-SRC1 from Abcam) or IgG controls and protein A/ G beads (Millipore). After extensive washing, DNA was eluted followed by reversion of the protein-DNA cross-linking. DNA was recovered for sequencing or qRT-PCR to quantify specific DNA fragments that were precipitated. Primers used for qRT-PCR are listed in Supplementary Table 1 . Two biological replicates for each condition were sequenced on an Illumina HiSeq 2500 to produce 51-bp reads.
Reads were aligned to the mm10 mouse genome using NovoAlign (http://www. novocraft.com/). TDF files were generated for visualization on the Integrative Genomics Viewer 53 . The enrichment of RORγt binding sites across the genome was analyzed using MACS2 with '-nomodel-extsize 150' 54 . The irreproducible discovery rate (IDR) framework was utilized find reproducible peaks across replicates. Enriched known TF motifs in ChIP-seq peaks were identified by using HOMER (findMotifsGenome.pl) 55 .
Quantitative real-time PCR. qRT-PCR was performed using SsoFast EvaGreen Supermix (Bio-Rad) in a CFX96 Real-Time PCR Detection System (Bio-Rad), using the primers listed in Supplementary Table 1 . The amplification efficiency of all primers was previously tested, and the optimized conditions were used for all qRT-PCR reactions. Expression was calculated using the ΔΔxp method normalized to β-actin, and all measurements were performed in triplicate.
Apoptosis assays. Thymocytes were freshly isolated from WT, RORγt −/− , or RORγt K31R/K31R mice and cultured in RPMI 1640 medium supplemented with 10% FBS, 100 U/ml penicillin-streptomycin, and 2 mM L-glutamine at 1 × 10 6 cells/ml. Thymocytes were incubated at 37°C with 5% CO 2 . Dead cells were detected using Annexin V-PE and 7-AAD staining (BD Bioscience).
Induction and assessment of EAE. Active EAE was induced using an EAE induction kit, according to the manufacturer's instructions (Hooke Laboratories, Lawrence, MA). Briefly, mice were subcutaneously immunized with a 200-ml myelin oligodendrocyte glycoprotein 35-55 (MOG ) peptide emulsion. On days 0 and 1 after immunization, mice were injected intraperitoneally with 200 ng Bordetella pertussis toxin. For T H 17-or T H 1-induced passive EAE, donor mice were immunized with MOG subcutaneously. 10 days later, cells were isolated from the spleen and lymph nodes and cultured with 20 µg/ml MOG 35-55 for 3 days under either T H 17-polarizing conditions (20 ng/ml rmIL23) or T H 1-polarizing conditions (20 ng/ml rmIL-12; 2 µg/ml α-IL23p19). Rag1 −/− recipient mice were then intraperitoneally transferred 3.0 × 10 7 MOG 35-55 -specific T H 17 or T H 1 cells. The severity of EAE was monitored and evaluated on a scale from 0 to 5 according to the Hooke Laboratories guidelines: 0 = no disease; 1 = paralyzed tail; 2 = hind limb weakness; 3 = hind limb paralysis; 4 = hind and forelimb paralysis; and 5 = moribund and death. When a mouse was euthanized because of severe paralysis, a score of 5 was entered for that mouse for the rest of the experiment.
Immunoprecipitation and immunoblot analysis. Cells were lysed in lysis buffer (1% Triton X-100, 20 mM Tris-cl, pH 7.4, 150 mM NaCl, and 5 mM EDTA) supplemented with protease inhibitor cocktail (Sigma) and 1 mM PMSF. Cell extracts were incubated overnight with 1 µg of the relevant antibodies, and proteins were immunoprecipitated for an additional 1 h at 4°C with protein A/G-Sepharose beads (milipore). To detect sumoylation, transfected HEK293T cells, primary thymocytes, or polarized T H 17 cells were lysed in lysis buffer containing 20 mM Nethylmaleimide. Supernatant was supplemented with 1% SDS (vol/vol) and heated at 90°C for 10 min. Samples were then diluted (1:10) with lysis buffer and incubated with anti-RORγt at 4°C overnight. Enrichment of ubiquitinated proteins was performed as previously described 44 . Briefly, cell lysates were incubated with equilibrated Agarose-coupled Tandem Ubiquitin Binding Entity 1 (Agarose-TUBE1) (LifeSensors) at 4°C for 4 h. After incubation, beads were washed four times with lysis buffer, resolved using SDS-PAGE, and analyzed using Western blot.
Statistical analysis. Prism software (GraphPad) was used for all statistical analyses. Two-tailed unpaired Student's t-tests and one-way analysis of variance (ANOVA) were used to compare experimental groups. A P-value of less than 0.05 was considered statistically significant.
Data availability
The data that support the findings of this study are available from the corresponding author upon request. The SRA (Sequence Read Archive) accession code for RNA-seq and ChIP-seq data is SRP150962. 
